

Stephen J Clarke

List of Publications by Citations

Source: <https://exaly.com/author-pdf/391072/stephen-j-clarke-publications-by-citations.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

278
papers

15,088
citations

56
h-index

118
g-index

288
ext. papers

17,577
ext. citations

4.6
avg. IF

6.37
L-index

#	Paper	IF	Citations
278	Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. <i>Journal of Clinical Oncology</i> , 2008 , 26, 2013-9	2.2	2328
277	Cancer-related inflammation and treatment effectiveness. <i>Lancet Oncology, The</i> , 2014 , 15, e493-503	21.7	945
276	The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2013 , 88, 218-30	7	827
275	Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 2006-12	2.2	667
274	Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. <i>Lancet Oncology, The</i> , 2012 , 13, 1225-33	21.7	389
273	Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. <i>British Journal of Cancer</i> , 2011 , 104, 1288-95	8.7	334
272	Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. <i>Lancet Oncology, The</i> , 2017 , 18, 1386-1396	21.7	330
271	Clinical pharmacokinetics of docetaxel. <i>Clinical Pharmacokinetics</i> , 1999 , 36, 99-114	6.2	328
270	A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. <i>British Journal of Cancer</i> , 2012 , 107, 695-9	8.7	290
269	High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. <i>Clinical Cancer Research</i> , 2010 , 16, 5805-13	12.9	238
268	Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2532-2537	2.2	217
267	First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. <i>Lancet Oncology, The</i> , 2017 , 18, 1159-1171	21.7	193
266	Cancer patient disclosure and patient-doctor communication of complementary and alternative medicine use: a systematic review. <i>Oncologist</i> , 2012 , 17, 1475-81	5.7	189
265	Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. <i>Lancet Oncology, The</i> , 2003 , 4, 224-32	21.7	181
264	The Lymphocyte-to-Monocyte Ratio is a Superior Predictor of Overall Survival in Comparison to Established Biomarkers of Resectable Colorectal Cancer. <i>Annals of Surgery</i> , 2017 , 265, 539-546	7.8	165
263	XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. <i>British Journal of Cancer</i> , 2011 , 105, 58-64	8.7	160
262	Effect of medical Qigong on cognitive function, quality of life, and a biomarker of inflammation in cancer patients: a randomized controlled trial. <i>Supportive Care in Cancer</i> , 2012 , 20, 1235-42	3.9	152

261	Inflammation and cancer: causes and consequences. <i>Clinical Pharmacology and Therapeutics</i> , 2010 , 87, 504-8	6.1	149
260	Impact of medical Qigong on quality of life, fatigue, mood and inflammation in cancer patients: a randomized controlled trial. <i>Annals of Oncology</i> , 2010 , 21, 608-614	10.3	143
259	The relationship between available support, unmet needs and caregiver burden in patients with advanced cancer and their carers. <i>Psycho-Oncology</i> , 2005 , 14, 102-14	3.9	134
258	Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer. <i>Epigenomics</i> , 2016 , 8, 1079-85	4.4	124
257	Cognitive Function in Patients With Colorectal Cancer Who Do and Do Not Receive Chemotherapy: A Prospective, Longitudinal, Controlled Study. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4085-92	2.2	122
256	Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance. <i>Theranostics</i> , 2017 , 7, 1149-1158	12.1	115
255	Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2019 , 111, 782-794	9.7	113
254	BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome. <i>American Journal of Surgical Pathology</i> , 2013 , 37, 1592-602	6.7	112
253	Evaluation of nutritional and inflammatory status of advanced colorectal cancer patients and its correlation with survival. <i>Nutrition and Cancer</i> , 2006 , 55, 78-85	2.8	112
252	Factors affecting cytochrome P-450 3A activity in cancer patients. <i>Clinical Cancer Research</i> , 2004 , 10, 8341-50	12.9	107
251	Diagnosis of gastrointestinal bleeding: A practical guide for clinicians. <i>World Journal of Gastrointestinal Pathophysiology</i> , 2014 , 5, 467-78	3.2	103
250	Activation of thermogenesis in brown adipose tissue and dysregulated lipid metabolism associated with cancer cachexia in mice. <i>Cancer Research</i> , 2012 , 72, 4372-82	10.1	100
249	Nutrition intervention using an eicosapentaenoic acid (EPA)-containing supplement in patients with advanced colorectal cancer. Effects on nutritional and inflammatory status: a phase II trial. <i>Supportive Care in Cancer</i> , 2007 , 15, 301-7	3.9	96
248	Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. <i>Oncology</i> , 2009 , 77, 113-9	3.6	94
247	Pharmacometabonomic profiling as a predictor of toxicity in patients with inoperable colorectal cancer treated with capecitabine. <i>Clinical Cancer Research</i> , 2011 , 17, 3019-28	12.9	90
246	Nutritional assessment in cancer: comparing the Mini-Nutritional Assessment (MNA) with the scored Patient-Generated Subjective Global Assessment (PGSGA). <i>Nutrition and Cancer</i> , 2005 , 53, 51-6	2.8	90
245	Ethnic differences in drug metabolism and toxicity from chemotherapy. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2009 , 5, 243-57	5.5	89
244	Systemic inflammatory response predicts prognosis in patients with advanced-stage colorectal cancer. <i>Clinical Colorectal Cancer</i> , 2008 , 7, 331-7	3.8	82

243	Supporting treatment decision making in advanced cancer: a randomized trial of a decision aid for patients with advanced colorectal cancer considering chemotherapy. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2077-84	2.2	81
242	Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients. <i>Clinical Cancer Research</i> , 2008 , 14, 817-25	12.9	81
241	The relationship between body image disturbance and distress in colorectal cancer patients with and without stomas. <i>Journal of Psychosomatic Research</i> , 2011 , 70, 395-402	4.1	77
240	Cognitive function and fatigue after diagnosis of colorectal cancer. <i>Annals of Oncology</i> , 2014 , 25, 2404-2412	10.3	76
239	Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2009 , 101, 998-1004	8.7	73
238	Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer. <i>Gut</i> , 2018 , 67, 2142-2155	19.2	71
237	Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 1923-9	8.9	71
236	Patient and physician preferences for surgical and adjuvant treatment options for rectal cancer. <i>Archives of Surgery</i> , 2008 , 143, 389-94		69
235	Baseline nutritional assessment in advanced cancer patients receiving palliative chemotherapy. <i>Nutrition and Cancer</i> , 2003 , 46, 148-57	2.8	68
234	Randomized controlled trial of a structured intervention to facilitate end-of-life decision making in patients with advanced cancer. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3403-10	2.2	65
233	Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2008 , 4, 137-49	5.5	64
232	Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer. <i>Clinical Cancer Research</i> , 2006 , 12, 7492-7	12.9	64
231	Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project. <i>Journal of the National Cancer Institute</i> , 2018 , 110, 638-648	9.7	63
230	MicroRNA-7 as a tumor suppressor and novel therapeutic for adrenocortical carcinoma. <i>Oncotarget</i> , 2015 , 6, 36675-88	3.3	62
229	The relationship between nutritional status, inflammatory markers and survival in patients with advanced cancer: a prospective cohort study. <i>Supportive Care in Cancer</i> , 2015 , 23, 385-91	3.9	60
228	Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics. <i>Clinical Pharmacokinetics</i> , 2012 , 51, 203-24	6.2	60
227	A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers. <i>Journal of the National Cancer Institute</i> , 2019 , 111, 575-583	9.7	60
226	Medical Qigong for cancer patients: pilot study of impact on quality of life, side effects of treatment and inflammation. <i>The American Journal of Chinese Medicine</i> , 2008 , 36, 459-72	6	59

225	The use and perceived benefits resulting from the use of complementary and alternative medicine by cancer patients in Australia. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2010 , 6, 342-9	1.9	58
224	Disruption of MEF2C signaling and loss of sarcomeric and mitochondrial integrity in cancer-induced skeletal muscle wasting. <i>Aging</i> , 2012 , 4, 133-43	5.6	58
223	Use of inflammatory markers to guide cancer treatment. <i>Clinical Pharmacology and Therapeutics</i> , 2011 , 90, 475-8	6.1	55
222	Src tyrosine kinase phosphorylation of nuclear receptor HNF4 α correlates with isoform-specific loss of HNF4 α in human colon cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 2302-7	11.5	55
221	A Significant Metabolic and Radiological Response after a Novel Targeted MicroRNA-based Treatment Approach in Malignant Pleural Mesothelioma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015 , 191, 1467-9	10.2	54
220	Population pharmacokinetics of weekly docetaxel in patients with advanced cancer. <i>British Journal of Clinical Pharmacology</i> , 2004 , 57, 44-53	3.8	54
219	Depletion of white adipose tissue in cancer cachexia syndrome is associated with inflammatory signaling and disrupted circadian regulation. <i>PLoS ONE</i> , 2014 , 9, e92966	3.7	54
218	Impact of physical activity on fatigue and quality of life in people with advanced lung cancer: a randomized controlled trial. <i>Annals of Oncology</i> , 2017 , 28, 1889-1897	10.3	53
217	Symptom Clusters in Advanced Cancer Patients: An Empirical Comparison of Statistical Methods and the Impact on Quality of Life. <i>Journal of Pain and Symptom Management</i> , 2016 , 51, 88-98	4.8	53
216	Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, 317-24	3.3	53
215	Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales. <i>British Journal of Cancer</i> , 2014 , 111, 1860-9	8.7	52
214	The erythromycin breath test for the prediction of drug clearance. <i>Clinical Pharmacokinetics</i> , 2001 , 40, 151-8	6.2	52
213	Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study. <i>European Journal of Cancer</i> , 2019 , 109, 28-35	7.5	50
212	Neutrophil to lymphocyte ratio and early clinical outcomes in patients with acute ischemic stroke. <i>Journal of the Neurological Sciences</i> , 2018 , 387, 115-118	3.2	50
211	Changes in quality of life in patients with advanced cancer: evidence of response shift and response restriction. <i>Journal of Psychosomatic Research</i> , 2005 , 58, 497-504	4.1	49
210	Oxidative stress in prostate cancer patients: A systematic review of case control studies. <i>Prostate International</i> , 2016 , 4, 71-87	3.4	49
209	Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board. <i>Clinical Lung Cancer</i> , 2013 , 14, 70-7	4.9	48
208	Comprehensive glycomics comparison between colon cancer cell cultures and tumours: implications for biomarker studies. <i>Journal of Proteomics</i> , 2014 , 108, 146-62	3.9	47

207	Cancer-Related Systemic Inflammation: The Challenges and Therapeutic Opportunities for Personalized Medicine. <i>Clinical Pharmacology and Therapeutics</i> , 2017 , 102, 599-610	6.1	47
206	Accuracy of diagnostic biopsy for the histological subtype of malignant pleural mesothelioma. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 602-5	8.9	47
205	Systemic inflammation is an independent predictive marker of clinical outcomes in mucosal squamous cell carcinoma of the head and neck in oropharyngeal and non-oropharyngeal patients. <i>BMC Cancer</i> , 2016 , 16, 124	4.8	45
204	Body image as a predictor of psychopathology in surgical patients with colorectal disease. <i>Journal of Psychosomatic Research</i> , 2012 , 73, 459-63	4.1	44
203	Clinical management and treatment outcomes of Merkel cell carcinoma. <i>ANZ Journal of Surgery</i> , 1998 , 68, 354-8	1	43
202	The ticking time-bomb of asbestos: its insidious role in the development of malignant mesothelioma. <i>Critical Reviews in Oncology/Hematology</i> , 2012 , 84, 200-12	7	42
201	Somatostatin Receptor SSTR-2a Expression Is a Stronger Predictor for Survival Than Ki-67 in Pancreatic Neuroendocrine Tumors. <i>Medicine (United States)</i> , 2015 , 94, e1281	1.8	41
200	Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study. <i>BMC Cancer</i> , 2014 , 14, 897	4.8	41
199	CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin. <i>Pharmacogenomics</i> , 2013 , 14, 137-49	2.6	40
198	KRAS mutations and CDKN2A promoter methylation show an interactive adverse effect on survival and predict recurrence of rectal cancer. <i>International Journal of Cancer</i> , 2014 , 134, 2820-8	7.5	39
197	A critical review of the effects of medical Qigong on quality of life, immune function, and survival in cancer patients. <i>Integrative Cancer Therapies</i> , 2012 , 11, 101-10	3	39
196	Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target. <i>Histopathology</i> , 2017 , 70, 402-411	7.3	38
195	Safety, efficacy and pharmacodynamics (PD) of MEDI9447 (oleclumab) alone or in combination with durvalumab in advanced colorectal cancer (CRC) or pancreatic cancer (panc).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4123-4123	2.2	38
194	Fatigue in people with localized colorectal cancer who do and do not receive chemotherapy: a longitudinal prospective study. <i>Annals of Oncology</i> , 2016 , 27, 1761-7	10.3	37
193	Neutrophil-to-lymphocyte ratio in head and neck cancer. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2015 , 59, 514-519	1.7	36
192	Preoperative neutrophil/lymphocyte ratio predicts overall survival but does not predict recurrence or cancer-specific survival after curative resection of node-positive colorectal cancer. <i>BMC Cancer</i> , 2013 , 13, 442	4.8	35
191	Clinical and imaging-based prognostic factors in radioembolisation of liver metastases from colorectal cancer: a retrospective exploratory analysis. <i>EJNMMI Research</i> , 2017 , 7, 46	3.6	34
190	Liver membrane proteome glycosylation changes in mice bearing an extra-hepatic tumor. <i>Molecular and Cellular Proteomics</i> , 2011 , 10, M900538MCP200	7.6	34

189	The development of multiple reaction monitoring assays for liver-derived plasma proteins. <i>Proteomics - Clinical Applications</i> , 2007 , 1, 1570-81	3.1	34
188	Prognostic and predictive biomarkers in neuroendocrine tumours. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 113, 268-282	7	33
187	A data-driven, knowledge-based approach to biomarker discovery: application to circulating microRNA markers of colorectal cancer prognosis. <i>Npj Systems Biology and Applications</i> , 2018 , 4, 20	5	33
186	Health-related quality of life and inflammatory markers in malignant pleural mesothelioma. <i>Supportive Care in Cancer</i> , 2013 , 21, 697-705	3.9	33
185	Adjuvant chemotherapy for early colon cancer: what survival benefits make it worthwhile?. <i>European Journal of Cancer</i> , 2010 , 46, 1800-7	7.5	33
184	Adverse tumor biology associated with mesenterico-portal vein resection influences survival in patients with pancreatic ductal adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2014 , 21, 1937-47	3.1	32
183	Using the Distress Thermometer and Hospital Anxiety and Depression Scale to screen for psychosocial morbidity in patients diagnosed with colorectal cancer. <i>Journal of Affective Disorders</i> , 2011 , 131, 412-6	6.6	32
182	Eligibility of patients with advanced non-small cell lung cancer for phase III chemotherapy trials. <i>BMC Cancer</i> , 2009 , 9, 130	4.8	32
181	Identification of distinctive protein expression patterns in colorectal adenoma. <i>Proteomics - Clinical Applications</i> , 2010 , 4, 60-70	3.1	32
180	Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies. <i>Clinical Colorectal Cancer</i> , 2018 , 17, e617-e629	3.8	31
179	Systemic inflammation and prediction of chemotherapy outcomes in patients receiving docetaxel for advanced cancer. <i>Supportive Care in Cancer</i> , 2012 , 20, 1869-74	3.9	31
178	Fascin expression predicts survival after potentially curative resection of node-positive colon cancer. <i>American Journal of Surgical Pathology</i> , 2010 , 34, 656-66	6.7	31
177	Cetuximab-associated pulmonary toxicity. <i>Clinical Colorectal Cancer</i> , 2009 , 8, 118-20	3.8	31
176	Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2011 , 79, 224-50	7	30
175	A randomised controlled trial of an advance care planning intervention for patients with incurable cancer. <i>British Journal of Cancer</i> , 2018 , 119, 1182-1190	8.7	30
174	Glasgow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy. <i>Clinical Genitourinary Cancer</i> , 2013 , 11, 423-30	3.3	29
173	Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin. <i>Pharmacogenetics and Genomics</i> , 2013 , 23, 148-55	1.9	29
172	The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine. <i>Lung Cancer</i> , 2012 , 75, 248-54	5.9	28

171	Proteomic comparison of colorectal tumours and non-neoplastic mucosa from paired patient samples using iTRAQ mass spectrometry. <i>Molecular BioSystems</i> , 2011 , 7, 2997-3005		28
170	Relationship of hepatic functional imaging to irinotecan pharmacokinetics and genetic parameters of drug elimination. <i>Journal of Clinical Oncology</i> , 2006 , 24, 4228-35	2.2	28
169	A randomized controlled pilot trial comparing the impact of access to clinical endocrinology video demonstrations with access to usual revision resources on medical student performance of clinical endocrinology skills. <i>BMC Medical Education</i> , 2013 , 13, 135	3.3	27
168	Extrahepatic cancer suppresses nuclear receptor-regulated drug metabolism. <i>Clinical Cancer Research</i> , 2011 , 17, 3170-80	12.9	27
167	Predicting the toxicity of weekly docetaxel in advanced cancer. <i>Clinical Pharmacokinetics</i> , 2006 , 45, 611-22		27
166	Prognostic factors predictive of response and survival to a modified FOLFOX regimen: importance of an increased neutrophil count. <i>Clinical Colorectal Cancer</i> , 2006 , 6, 297-304	3.8	27
165	Surface antigen profiling of colorectal cancer using antibody microarrays with fluorescence multiplexing. <i>Journal of Immunological Methods</i> , 2010 , 355, 40-51	2.5	26
164	Malignant mesothelioma. <i>Internal Medicine Journal</i> , 2010 , 40, 742-50	1.6	25
163	Exhaled breath condensate for lung cancer protein analysis: a review of methods and biomarkers. <i>Journal of Breath Research</i> , 2016 , 10, 034001	3.1	25
162	Patient-doctor communication: use of complementary and alternative medicine by adult patients with cancer. <i>Society for Integrative Oncology</i> , 2010 , 8, 56-64		25
161	Validation of tissue microarray technology in malignant pleural mesothelioma. <i>Pathology</i> , 2011 , 43, 128-32		24
160	Retrospective cohort analysis of neoadjuvant treatment and survival in resectable and borderline resectable pancreatic ductal adenocarcinoma in a high volume referral centre. <i>European Journal of Surgical Oncology</i> , 2017 , 43, 1711-1717	3.6	22
159	The impact of physical activity on fatigue and quality of life in lung cancer patients: a randomised controlled trial protocol. <i>BMC Cancer</i> , 2012 , 12, 572	4.8	22
158	A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer. <i>Lung Cancer</i> , 2005 , 49, 401-12	5.9	22
157	An evaluation of the prevalence of malnutrition in cancer patients attending the outpatient oncology clinic. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2006 , 2, 80-86	1.9	22
156	Inflammatory (B) symptoms are independent predictors of myelosuppression from chemotherapy in Non-Hodgkin Lymphoma (NHL) patients--analysis of data from a British National Lymphoma Investigation phase III trial comparing CHOP to PMitCEBO. <i>BMC Cancer</i> , 2009 , 9, 153	4.8	21
155	Inflammation in malignant mesothelioma - friend or foe?. <i>Annals of Cardiothoracic Surgery</i> , 2012 , 1, 516-27		21
154	Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial. <i>Annals of Oncology</i> , 2020 , 31, 1553-1560	10.3	21

153	Improving Outcomes in Adrenocortical Cancer: An Australian Perspective. <i>Annals of Surgical Oncology</i> , 2015 , 22, 2309-16	3.1	19
152	Clinical and preclinical pharmacokinetics of raltitrexed. <i>Clinical Pharmacokinetics</i> , 2000 , 39, 429-43	6.2	19
151	The vermiform appendix: an immunological organ sustaining a microbiome inoculum. <i>Clinical Science</i> , 2019 , 133, 1-8	6.5	19
150	A Longitudinal Investigation of Inflammatory Markers in Colorectal Cancer Patients Perioperatively Demonstrates Benefit in Serial Remeasurement. <i>Annals of Surgery</i> , 2018 , 267, 1119-1125	7.8	18
149	Streptavidin: a novel immunostimulant for the selection and delivery of autologous and syngeneic tumor vaccines. <i>Cancer Immunology Research</i> , 2014 , 2, 469-79	12.5	18
148	Patient and oncologist estimates of survival in advanced cancer patients. <i>Psycho-Oncology</i> , 2011 , 20, 213-8	3.9	18
147	Overview of biomarkers in metastatic colorectal cancer: tumour, blood and patient-related factors. <i>Critical Reviews in Oncology/Hematology</i> , 2013 , 85, 121-35	7	17
146	Immunohistochemical validation of overexpressed genes identified by global expression microarrays in adrenocortical carcinoma reveals potential predictive and prognostic biomarkers. <i>Oncologist</i> , 2015 , 20, 247-56	5.7	16
145	A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer. <i>Lung Cancer</i> , 2020 , 142, 34-40	5.9	16
144	An Australian translational study to evaluate the prognostic role of inflammatory markers in patients with metastatic Colorectal cancer Treated with bevacizumab (Avastin) [®] [ASCENT]. <i>BMC Cancer</i> , 2013 , 13, 120	4.8	16
143	From mice to men: GEMMs as trial patients for new NSCLC therapies. <i>Seminars in Cell and Developmental Biology</i> , 2014 , 27, 118-27	7.5	16
142	Clinicopathological correlates and prognostic significance of maspin expression in 450 patients after potentially curative resection of node-positive colonic cancer. <i>Histopathology</i> , 2010 , 56, 319-30	7.3	16
141	Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: A multi-institutional cohort study. <i>European Journal of Surgical Oncology</i> , 2019 , 45, 218-224	3.6	16
140	High BIN1 expression has a favorable prognosis in malignant pleural mesothelioma and is associated with tumor infiltrating lymphocytes. <i>Lung Cancer</i> , 2019 , 130, 35-41	5.9	15
139	A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma. <i>British Journal of Cancer</i> , 2016 , 114, 524-31	8.7	15
138	Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C(14)-erythromycin breath test and the antipyrine clearance test. <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 69, 125-35	3.5	15
137	Patterns of care for malignant pleural mesothelioma patients compensated by the Dust Diseases Board in New South Wales, Australia. <i>Internal Medicine Journal</i> , 2013 , 43, 402-10	1.6	15
136	An update on ethnic differences in drug metabolism and toxicity from anti-cancer drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011 , 7, 1395-410	5.5	15

135	Multiplex detection of ctDNA mutations in plasma of colorectal cancer patients by PCR/SERS assay. <i>Nanotheranostics</i> , 2020 , 4, 224-232	5.6	15
134	Cyto-Immuno-Therapy for Cancer: A Pathway Elicited by Tumor-Targeted, Cytotoxic Drug-Packaged Bacterially Derived Nanocells. <i>Cancer Cell</i> , 2020 , 37, 354-370.e7	24.3	14
133	Advance care planning in patients with incurable cancer: study protocol for a randomised controlled trial. <i>BMJ Open</i> , 2016 , 6, e012387	3	14
132	Extra-hepatic cancer represses hepatic drug metabolism via interleukin (IL)-6 signalling. <i>Pharmaceutical Research</i> , 2013 , 30, 2270-8	4.5	14
131	Validation of a minimal panel of antibodies for the diagnosis of malignant pleural mesothelioma. <i>Pathology</i> , 2011 , 43, 313-7	1.6	14
130	Advances in the adjuvant treatment of colorectal cancer. <i>ANZ Journal of Surgery</i> , 2006 , 76, 373-80	1	14
129	Systematic Review and Meta-Analysis on the Role of Chemotherapy in Advanced and Metastatic Neuroendocrine Tumor (NET). <i>PLoS ONE</i> , 2016 , 11, e0158140	3.7	14
128	Establishing a panel of chemo-resistant mesothelioma models for investigating chemo-resistance and identifying new treatments for mesothelioma. <i>Scientific Reports</i> , 2014 , 4, 6152	4.9	13
127	Challenges in chemotherapy delivery: comparison of standard chemotherapy delivery to locoregional vascular mass fluid transfer. <i>Future Oncology</i> , 2018 , 14, 647-663	3.6	13
126	Investigation of herb-drug interactions with ginkgo biloba in women receiving hormonal treatment for early breast cancer. <i>SpringerPlus</i> , 2013 , 2, 126		13
125	The eligibility of advanced non-small-cell lung cancer patients for targeted therapy clinical trials. <i>Annals of Oncology</i> , 2012 , 23, 1229-1233	10.3	13
124	Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a study protocol for a pilot and definitive randomised double-blind placebo-controlled trial (CannabisCINV). <i>BMJ Open</i> , 2018 , 8, e020745	3	13
123	Multicenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLC. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2015 , 11, 4-14	1.9	12
122	Australian recommendations for EGFR T790M testing in advanced non-small cell lung cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017 , 13, 296-303	1.9	12
121	Australian recommendations for the management of hepatocellular carcinoma: a consensus statement. <i>Medical Journal of Australia</i> , 2021 , 214, 475-483	4	12
120	Identification of Novel Biomarkers in Pancreatic Tumor Tissue to Predict Response to Neoadjuvant Chemotherapy. <i>Frontiers in Oncology</i> , 2020 , 10, 237	5.3	11
119	Temporal and spatial modulation of the tumor and systemic immune response in the murine GL261 glioma model. <i>PLoS ONE</i> , 2020 , 15, e0226444	3.7	11
118	Extracellular vesicles as biomarkers in malignant pleural mesothelioma: A review. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 150, 102949	7	11

117	Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected]. <i>European Journal of Cancer</i> , 2011 , 47, 1826-36	7.5	11
116	The alternatively spliced murine pregnane X receptor isoform, mPXR(delta171-211) exhibits a repressive action. <i>International Journal of Biochemistry and Cell Biology</i> , 2010 , 42, 672-82	5.6	11
115	Clinical pharmacology of chemotherapy agents in older people with cancer. <i>Current Gerontology and Geriatrics Research</i> , 2011 , 2011, 628670	2.9	11
114	Clinical pharmacokinetics of the irinotecan metabolite 4-piperidinopiperidine and its possible clinical importance. <i>Cancer Chemotherapy and Pharmacology</i> , 2000 , 45, 9-14	3.5	11
113	Eastern Cooperative Oncology Group score: Agreement between non-small-cell lung cancer patients and their oncologists and clinical implications. <i>Cancer Treatment Communications</i> , 2016 , 5, 17-21		11
112	The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials. <i>Lung Cancer</i> , 2016 , 102, 21-27	5.9	10
111	Glutathione S-transferase Pi expression predicts response to adjuvant chemotherapy for stage C colon cancer: a matched historical control study. <i>BMC Cancer</i> , 2012 , 12, 196	4.8	10
110	Clinicopathological correlates and prognostic significance of glutathione S-transferase Pi expression in 468 patients after potentially curative resection of node-positive colonic cancer. <i>Histopathology</i> , 2011 , 59, 1057-70	7.3	10
109	Systematic Review of the Role of Targeted Therapy in Metastatic Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2017 , 104, 209-222	5.6	9
108	The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: A translational study [ASCENT]. <i>PLoS ONE</i> , 2020 , 15, e0229900	3.7	9
107	Malignant Cardiac Tamponade from Non-Small Cell Lung Cancer: Case Series from the Era of Molecular Targeted Therapy. <i>Journal of Clinical Medicine</i> , 2014 , 4, 75-84	5.1	9
106	Pathogenic PALB2 mutation in metastatic pancreatic adenocarcinoma and neuroendocrine tumour: A case report. <i>Molecular and Clinical Oncology</i> , 2015 , 3, 817-819	1.6	9
105	Colorectal cancer cell surface protein profiling using an antibody microarray and fluorescence multiplexing. <i>Journal of Visualized Experiments</i> , 2011 ,	1.6	9
104	Predictive markers for haematological toxicity of pemetrexed. <i>Current Drug Targets</i> , 2010 , 11, 48-57	3	9
103	The role of adjuvant probiotics to attenuate intestinal inflammatory responses due to cancer treatments. <i>Beneficial Microbes</i> , 2018 , 9, 899-916	4.9	9
102	Factors affecting whether or not cancer patients consider using acupuncture. <i>Acupuncture in Medicine</i> , 2017 , 35, 107-113	1.9	8
101	Complete response in a patient with stage IV adrenocortical carcinoma treated with adjuvant trans-catheter arterial chemo-embolization (TACE). <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018 , 14, 279-281	1.9	8
100	Mass Cytometry Reveals a Sustained Reduction in CD16 Natural Killer Cells Following Chemotherapy in Colorectal Cancer Patients. <i>Frontiers in Immunology</i> , 2019 , 10, 2584	8.4	8

99	Use of cancer therapy at the end of life in patients with malignant pleural mesothelioma. <i>Supportive Care in Cancer</i> , 2013 , 21, 1879-84	3.9	8
98	Excision repair cross complementation group 1 and thymidylate synthase expression in patients with mesothelioma. <i>Clinical Lung Cancer</i> , 2013 , 14, 164-71	4.9	8
97	High Metabolic Tumour Volume on 18-Fluorodeoxyglucose Positron Emission Tomography Predicts Poor Survival from Neuroendocrine Neoplasms. <i>Neuroendocrinology</i> , 2020 , 110, 950-958	5.6	8
96	The Effects of Acupuncture on Cancer-Related Fatigue: Updated Systematic Review and Meta-Analysis. <i>Integrative Cancer Therapies</i> , 2020 , 19, 1534735420949679	3	8
95	Acupuncture in Oncology: The Effectiveness of Acupuncture May Not Depend on Needle Retention Duration. <i>Integrative Cancer Therapies</i> , 2018 , 17, 458-466	3	8
94	Localized malignant pleural mesothelioma with renal metastasis. <i>Oxford Medical Case Reports</i> , 2015 , 2015, 170-2	0.6	7
93	The role of proteomics in the age of immunotherapies. <i>Mammalian Genome</i> , 2018 , 29, 757-769	3.2	7
92	Overexpression of protein S100A4 is independently associated with overall survival in stage C colonic cancer but only in cytoplasm at the advancing tumour front. <i>International Journal of Colorectal Disease</i> , 2012 , 27, 1409-17	3	7
91	Patient-reported experience of the impact and burden of neuroendocrine tumors: Oceania patient results from a large global survey. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018 , 14, 256-263	1.9	7
90	The Gut Microbiome and Cancer Immunotherapy: Can We Use the Gut Microbiome as a Predictive Biomarker for Clinical Response in Cancer Immunotherapy?. <i>Cancers</i> , 2021 , 13,	6.6	7
89	Tumor sidedness is not an independent prognostic marker of colorectal cancer patients undergoing curative resection: A retrospective cohort study. <i>PLoS ONE</i> , 2019 , 14, e0218207	3.7	6
88	Reporting in studies of protein biomarkers of prognosis in colorectal cancer in relation to the REMARK guidelines. <i>Proteomics - Clinical Applications</i> , 2015 , 9, 1078-86	3.1	6
87	The Effects of Tai Chi and Qigong on Immune Responses: A Systematic Review and Meta-Analysis. <i>Medicines (Basel, Switzerland)</i> , 2020 , 7,	4.1	6
86	Altered cytochrome 2E1 and 3A P450-dependent drug metabolism in advanced ovarian cancer correlates to tumour-associated inflammation. <i>British Journal of Pharmacology</i> , 2019 , 176, 3712-3722	8.6	6
85	Surface profiles of live colorectal cancer cells and tumor infiltrating lymphocytes from surgical samples correspond to prognostic categories. <i>Journal of Immunological Methods</i> , 2015 , 416, 59-68	2.5	6
84	Remarkable temporal stability of high-abundance human plasma proteins assessed by targeted mass spectrometry. <i>Proteomics - Clinical Applications</i> , 2012 , 6, 626-34	3.1	6
83	Immunohistochemistry in the diagnosis of malignant pleural mesothelioma: trends in Australia and a literature review. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2013 , 9, 273-9	1.9	6
82	Estimating survival in advanced cancer: a comparison of estimates made by oncologists and patients. <i>Supportive Care in Cancer</i> , 2020 , 28, 3399-3407	3.9	6

81	EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non-Small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2021 , 22, e859-e869	4.9	6
80	Analytical performance of nano-LC-SRM using nondepleted human plasma over an 18-month period. <i>Proteomics</i> , 2016 , 16, 2118-27	4.8	6
79	Influence of molecular classification in anaplastic glioma for determining outcome and future approach to management. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2019 , 63, 272-280	1.7	5
78	Red blood cells exposed to cancer cells in culture have altered cytokine profiles and immune function. <i>Scientific Reports</i> , 2020 , 10, 7727	4.9	5
77	Adjuvant Iodine (131) Lipiodol after Resection of Hepatocellular Carcinoma. <i>Journal of Oncology</i> , 2015 , 2015, 746917	4.5	5
76	Clinical trial information as a measure of quality cancer care. <i>Journal of Oncology Practice</i> , 2010 , 6, 170-13.1		5
75	Relationship between PD-L1 expression and outcome in EGFR-mutant lung cancer patients treated with EGFR tyrosine kinase inhibitors. <i>Lung Cancer</i> , 2021 , 155, 28-33	5.9	5
74	Emerging Evidence of the Gut Microbiome in Chemotherapy: A Clinical Review. <i>Frontiers in Oncology</i> , 2021 , 11, 706331	5.3	5
73	Treatment and management of adrenal cancer in a specialized Australian endocrine surgical unit: approaches, outcomes and lessons learnt. <i>ANZ Journal of Surgery</i> , 2019 , 89, 48-52	1	4
72	Mouse Model of Mutated in Colorectal Cancer Gene Deletion Reveals Novel Pathways in Inflammation and Cancer. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2019 , 7, 819-839	7.9	4
71	Estimation of an optimal chemotherapy utilization rate for malignant pleural mesothelioma: an evidence-based benchmark for cancer care. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2015 , 11, 85-92	1.9	4
70	ALK-Rearranged Non-Small Cell Lung Cancer in 2020: Real-World Triumphs in an Era of Multigeneration ALK-Inhibitor Sequencing Informed by Drug Resistance Profiling. <i>Oncologist</i> , 2020 , 25, 641-649	5.7	4
69	Pattern of care and survival of anaplastic lymphoma kinase rearranged non-small cell lung cancer (ALK+ NSCLC) in an Australian Metropolitan Tertiary Referral Centre: A retrospective cohort analysis. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018 , 14, e275-e282	1.9	4
68	Accreditation Standard Guideline Initiative for Tai Chi and Qigong Instructors and Training Institutions. <i>Medicines (Basel, Switzerland)</i> , 2018 , 5,	4.1	4
67	Adjuvant chemotherapy for stage C colonic cancer in a multidisciplinary setting. <i>ANZ Journal of Surgery</i> , 2009 , 79, 685-92	1	4
66	A Critical Assessment of Postneoadjuvant Therapy Pancreatic Cancer Regression Grading Schemes With a Proposal for a Novel Approach. <i>American Journal of Surgical Pathology</i> , 2021 , 45, 394-404	6.7	4
65	Diagnostic Accuracy of Imaging Modalities in the Evaluation of Vascular Invasion in Pancreatic Adenocarcinoma: A Meta-Analysis. <i>World Journal of Oncology</i> , 2013 , 4, 74-82	16.7	4
64	Increased rates of cetuximab reactions in tick prevalent regions and a proposed protocol for risk mitigation. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021 , 17, 448-453	1.9	4

63	Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program. <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 1758835921-1019675	5.4	4
62	Evaluation of Fluorodeoxyglucose Positron Emission Tomography Scanning in the Neoadjuvant Therapy Paradigm in Pancreatic Ductal Adenocarcinoma. <i>Pancreas</i> , 2020 , 49, 224-229	2.6	3
61	Sub-acute Toxicity in Non-cancerous Tissue and Immune-Related Adverse Events of a Novel Combination Therapy for Cancer. <i>Frontiers in Oncology</i> , 2019 , 9, 1504	5.3	3
60	Prognostic indices of inflammatory markers, cognitive function and fatigue for survival in patients with localised colorectal cancer. <i>ESMO Open</i> , 2018 , 3, e000302	6	3
59	Safety and Feasibility of Repeatable Hepatic Vascular Isolation Chemotherapy: A Pilot Study. <i>Annals of Surgical Oncology</i> , 2016 , 23, 3699-3708	3.1	3
58	Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial. <i>International Journal of Cancer</i> , 2017 , 140, 431-439	7.5	3
57	Comment on Existing prognostic models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma. <i>British Journal of Cancer</i> , 2014 , 111, 2376	8.7	3
56	A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer. <i>Oncology Reports</i> , 2012 , 28, 763-7	3.5	3
55	The impact of neutrophil-lymphocyte ratio on risk reclassification of patients with advanced renal cell cancer to guide risk-directed therapy. <i>Acta Oncologica</i> , 2020 , 59, 20-27	3.2	3
54	Computed tomography (CT)-defined sarcopenia and myosteatosis are prevalent in patients with neuroendocrine neoplasms (NENs) treated with peptide receptor radionuclide therapy (PRRT). <i>European Journal of Clinical Nutrition</i> , 2021 ,	5.2	3
53	Safety and efficacy of the anti-CD73 monoclonal antibody (mAb) oleclumab ± durvalumab in patients (pts) with advanced colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), or EGFR-mutant non-small cell lung cancer (EGFRm NSCLC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9047-9047	2.2	3
52	The Gut Microbiome and Gastrointestinal Toxicities in Pelvic Radiation Therapy: A Clinical Review. <i>Cancers</i> , 2021 , 13,	6.6	3
51	Inability of Current Dosing to Achieve Carboplatin Therapeutic Targets in People with Advanced Non-Small Cell Lung Cancer: Impact of Systemic Inflammation on Carboplatin Exposure and Clinical Outcomes. <i>Clinical Pharmacokinetics</i> , 2020 , 59, 1013-1026	6.2	2
50	Modification of leucovorin dose within a simplified FOLFOX regimen improves tolerability without compromising efficacy. <i>Clinical Colorectal Cancer</i> , 2007 , 6, 578-82	3.8	2
49	Retrospective review of mitomycin C use as third-line chemotherapy in metastatic colorectal cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2008 , 4, 132-136	1.9	2
48	Unusual presentations of germ cell tumors. Case 1. Recurrent laryngeal nerve palsy in mediastinal seminoma. <i>Journal of Clinical Oncology</i> , 2001 , 19, 909-11	2.2	2
47	Vinblastine pharmacokinetics in patients with non-small cell lung cancer given cisplatin. <i>Cancer Investigation</i> , 1999 , 17, 479-85	2.1	2
46	Cognitive function and fatigue in colorectal cancer (CRC) patients: A prospective longitudinal controlled study.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 9021-9021	2.2	2

45	Serum bicarbonate is a marker of peri-operative mortality but is not associated with long term survival in colorectal cancer. <i>PLoS ONE</i> , 2020 , 15, e0228466	3.7	2
44	Changing Therapeutic Paradigms: Predicting mCRC Lesion Response to Selective Internal Radionuclide Therapy (SIRT) based on Critical Absorbed Dose Thresholds: A Case Study. <i>Asia Oceania Journal of Nuclear Medicine and Biology</i> , 2017 , 5, 66-69	0.7	2
43	Emerging biological therapies for the treatment of malignant pleural mesothelioma. <i>Expert Opinion on Emerging Drugs</i> , 2021 , 26, 179-192	3.7	2
42	Inflammatory Markers Have a Role in Renal Cell Carcinoma Prognosis. <i>European Urology Focus</i> , 2016 , 2, 341-342	5.1	2
41	Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions. <i>Lung Cancer</i> , 2021 , 159, 66-73	5.9	2
40	Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of neoadjuvant therapy. <i>European Journal of Surgical Oncology</i> , 2021 , 47, 2543-2556	3.6	2
39	Straddling medical specialties: should we have more comprehensive advanced training?. <i>Internal Medicine Journal</i> , 2019 , 49, 669-671	1.6	1
38	Use of adjuvant chemotherapy in stage C (III) rectal cancer: comparison of data from matched patients in a teaching hospital@ clinico-pathological database. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2012 , 8, 346-55	1.9	1
37	Vitamin supplementation in patients receiving pemetrexed for advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2013 , 82, 511	5.9	1
36	Randomized phase 2 sequencing and pharmacokinetic study of gemcitabine and oxaliplatin in advanced non-small cell lung cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2011 , 7, 376-84	1.9	1
35	Is it prime time for personalized medicine in cancer treatment?. <i>Personalized Medicine</i> , 2010 , 7, 387-397	2.2	1
34	Prognostic stratification of post-docetaxel metastatic castration resistant prostate cancer (mCRPC) from a phase III randomized trial.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4644-4644	2.2	1
33	Effects of qigong on quality of life, fatigue, stress, neuropathy, and sexual function in women with metastatic breast cancer: A feasibility study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e20712-e20712	2.2	1
32	Preliminary direct evidence of a dose-response relationship for [Y-90]-microsphere selective internal radionuclide therapy (SIRT) in hepatic malignancy.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 11064-11064 ¹	2.2	1
31	The impact of physical activity on fatigue and quality of life in lung cancer patients: A randomised controlled trial (RCT).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 9507-9507	2.2	1
30	Life-threatening diarrhea in neuroendocrine tumors: two case reports. <i>Journal of Medical Case Reports</i> , 2021 , 15, 542	1.2	1
29	Retrospective Evaluation of the Use of Pembrolizumab in Malignant Mesothelioma in a Real-World Australian Population. <i>JTO Clinical and Research Reports</i> , 2020 , 1, 100075	1.4	1
28	The lymphocyte-to-monocyte ratio as a predictor of overall survival in comparison to established systemic markers of inflammation in resectable colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 593-593	2.2	1

27	Plasma pre-treatment T790M relative allelic frequency in patients with advanced EGFR-mutated non-small cell lung cancer predicts treatment response to subsequent-line osimertinib. <i>Translational Lung Cancer Research</i> , 2021 , 10, 1623-1634	4.4	1
26	The integration of pharmacology and pathophysiology into locoregional chemotherapy delivery via mass fluid transfer. <i>Journal of Controlled Release</i> , 2018 , 292, 18-28	11.7	1
25	Osimertinib induced bullous dermatitis. <i>Cancer Treatment and Research Communications</i> , 2017 , 13, 25-26		0
24	Exploring the role of extracellular vesicles and their protein cargo in lung cancer metastasis: a review.. <i>Critical Reviews in Oncology/Hematology</i> , 2022 , 171, 103603	7	0
23	Liver Isolation Oxaliplatin (LIOX): Long Term Survival from a New Locoregional Technique for Chemorefractory Patients with Colorectal Liver Metastases.. <i>Annals of Surgical Oncology</i> , 2022 , 1	3.1	0
22	Effect of Cancer Pain Guideline Implementation on Pain Outcomes Among Adult Outpatients With Cancer-Related Pain: A Stepped Wedge Cluster Randomized Trial.. <i>JAMA Network Open</i> , 2022 , 5, e220060	10.4	0
21	Dramatic response to selective internal radiation therapy for unresectable hepatocellular carcinoma. <i>Oxford Medical Case Reports</i> , 2015 , 2015, 194-5	0.6	
20	PET monitoring of liver directed selective internal radionuclide therapy for metastatic gastro-oesophageal cancer. <i>BMJ Case Reports</i> , 2016 , 2016,	0.9	
19	Reporting clinical trial information: colorectal cancer trials at Sydney Cancer Centre. <i>Internal Medicine Journal</i> , 2012 , 42, 416-21	1.6	
18	PHYTOTHERAPIES 2015 , 536-553		
17	Enduring complete metabolic response in metastatic adenocarcinoma of the gastro-oesophageal junction. <i>Oxford Medical Case Reports</i> , 2014 , 2014, 105-6	0.6	
16	Prognostic significance of circulating secreted protein acidic and rich in cysteine (SPARC) in malignant pleural mesothelioma (MPM).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 7580-7580	2.2	
15	Old and new prognostic factors in a series of 910 patients with malignant pleural mesothelioma (MPM).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 7586-7586	2.2	
14	Prognostic utility of the preoperative neutrophil/lymphocyte ratio combined with BRAF and MMR status in colorectal cancer patients.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e14529-e14529	2.2	
13	Biomarkers in Metastatic Colorectal Cancer. <i>Biomarkers in Disease</i> , 2015 , 601-629		
12	Nomograms for overall survival (OS) and progression-free survival (PFS) in metastatic colorectal cancer (mCRC): Construction from 19,678 ARCAD patients.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 659-659 ²		
11	Neutrophil/lymphocyte ratio (NLR) and FDG PET as predictive measures of response and prognosis in patients treated with Y-90 microsphere selective internal radionuclide therapy (SIRT).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e22137-e22137	2.2	
10	Calculators for overall survival (OS) and progression-free survival (PFS) in metastatic colorectal cancer (mCRC): Construction from 19,678 ARCAD patients.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3555-3555 ²		

- | | | |
|---|---|-----|
| 9 | Adjuvant therapy in pancreatic adenocarcinoma: A systemic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 330-330 | 2.2 |
| 8 | Change in inflammatory status as a prognostic marker of overall survival in colorectal patients undergoing resection.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 6571-6571 | 2.2 |
| 7 | Beyond Conventional Cancer Treatments: "The Use of Complementary Therapies During Cancer Treatment: Implications for Clinicians" 2009 , 285-315 | |
| 6 | Successes, challenges and future directions 2011 , 84-95 | |
| 5 | Pathophysiology of Bone Metastases 2012 , 59-84 | |
| 4 | Use of inflammatory markers to triage cancer patients requiring nutritional assessment and interventions.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e17541-e17541 | 2.2 |
| 3 | Science and art of anticancer drug dosing: nine steps to personalised therapy. <i>Internal Medicine Journal</i> , 2020 , 50, 992-996 | 1.6 |
| 2 | Marked improvement in hyperammonaemic encephalopathy from multimodal treatment of metastatic neuroendocrine tumour. <i>BMJ Case Reports</i> , 2021 , 14, | 0.9 |
| 1 | Primary Pericardial Sarcoma with Right Atrial Invasion and Multiple Bilateral Pulmonary Metastases in a Patient with Hereditary Nonpolyposis Colorectal Cancer. <i>Case Reports in Oncological Medicine</i> , 2016 , 2016, 6208029 | 0.9 |